Seed · Healthtech

PulmoGate raises approximately JPY330 million in Seed funding

Beyond Next Ventures leads financing for the Nagoya medical technology startup’s lung disease platform.

PulmoGate has raised approximately JPY330 million in a Seed round through a third-party share allotment. Beyond Next Ventures, Inc. led the round, joined by Teijin Pharma, Mitsubishi UFJ Capital Co., Ltd. and STATION Ai Central Japan 2-go Fund.

The Nagoya University research spinout focuses on interstitial lung disease. It is developing a remote multidisciplinary review service that brings specialist expertise into second opinions.

From specialist review to clinical development

The company plans to expand the remote review service, strengthen clinical validation and build its medical AI development and regulatory team. It is also researching AI for diagnosis and treatment strategy, alongside applications for home monitoring and respiratory rehabilitation. These products remain in development.

Use of funds

Remote specialist second-opinion service expansion

Clinical validation and medical AI development

Treatment support and home monitoring research

Funding history

Seed · This round~¥330M

Sources

  1. 名古屋大学発医療AIスタートアップのPulmoGate、シードラウンドで総額約3.3億円を調達prtimes.jp · Nov 18, 2026